Premium
Therapeutic whole blood exchange in the management of methaemoglobinemia: Case series and systematic review of literature
Author(s) -
Singh Pawan,
Rakesh Kodati,
Agarwal Ritesh,
Tripathi Paramatma P.,
Dhooria Sahajal,
Sehgal Inderpaul S.,
Prasad Kuruswamy T.,
Hans Rekha,
Sharma Rattiram,
Sharma Navneet,
Lad Deepesh,
Aggarwal Ashutosh N.,
Muthu Valliappan
Publication year - 2020
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/tme.12666
Subject(s) - medicine , therapeutic plasma exchange , systematic review , adverse effect , intensive care unit , intensive care medicine , medline , surgery , political science , law
Background Therapeutic whole blood exchange (TWBE) has been used as an alternative when methylene blue (MB) fails in severe methaemoglobinemia. However, there are limited data on the efficacy and safety of TWBE. Objectives Our aim was to report our institutional experience with TWBE. We also perform a systematic review of published literature. Methods We retrospectively reviewed our respiratory intensive care unit database to identify cases of methaemoglobinemia managed with TWBE. A systematic review of the PubMed database was performed to identify similar cases (≥12 years). We report the indications, utility, and safety of therapeutic exchange in methaemoglobinemia. The procedural details were also noted. Results We identified five subjects who received TWBE for methaemoglobinemia (median methaemoglobin level 39%; range 19.6‐42.4%). TWBE was successful in all five cases and no adverse events were encountered. Our review identified 27 additional subjects. The median methaemoglobin level was 37.5% (range 3.7‐81%). The most common indication (n = 24, 75%) for therapeutic exchange was a lack of response to MB. A majority of the subjects (n = 26/32, 81.2%) survived. No procedure‐related complications were reported. Conclusion TWBE is a safe and effective salvage modality for adults with methaemoglobinemia, when MB is either contraindicated or ineffective. Future studies should standardise therapeutic exchange in the management of methaemoglobinemia.